Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy
- PMID: 20446847
- PMCID: PMC2873127
- DOI: 10.1086/652750
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy
Abstract
Background: To identify inflammatory pathways that may contribute to the pathogenesis of human immunodeficiency virus (HIV) disease, we explored associations between AIDS or death and different inflammatory markers, including selected soluble tumor necrosis factor superfamily receptors (sTNFRs) and ligands, interleukin (IL)-6, and CD8 T cell activation, in individuals treated with highly active antiretroviral therapy (HAART).
Methods: A case-control study of subjects in AIDS Clinical Trials Group (ACTG) protocols 384 and 5015, who were matched according to the CD4 cell count and plasma viral load at baseline, was performed using conditional logistic regression.
Results: Higher pretreatment concentrations of sTNFR-1, sCD27, sCD40L, and plasma IL-6 were associated with a new AIDS-defining illness or death in separate models adjusted for age, sex, hemoglobin, and the latest CD4 cell counts. In additional models that excluded case patients with opportunistic infections, sTNFR-1, sCD27, and sCD40L were each associated with a new AIDS-defining malignancy or death that developed at a median of 51 weeks after initiation of HAART, by which time the majority of subjects had a CD4 cell count of >200 cells/cm(3) and had achieved a plasma viral load of <50 copies/mL.
Conclusion: These data are compatible with a model in which these soluble inflammatory markers identify pathways that may contribute to the pathogenesis of HIV disease progression, pathways that might not be a direct consequence of ongoing HIV type 1 replication.
Conflict of interest statement
Conflicts of Interest:
R.T.G. received grant funding from Tibotec and Gilead and an honorarium from GlaxoSmith Kline.
R.B.P. is on the Speaker’s bureau for Bristol Meyers Squibb and Gilead.
G.K.R. received grant funding from Gilead, Schering-Plough, and consulting fees from Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals and Tibotec.
A.L. received honoraria from Abbott Laboratories and Bristol-Myers Squibb.
Figures
Comment in
-
Inflammation and complications of HIV disease.J Infect Dis. 2010 Jun 15;201(12):1783-5. doi: 10.1086/652751. J Infect Dis. 2010. PMID: 20446849 No abstract available.
References
-
- Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231–41. - PubMed
-
- Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis. 2005;191:694–701. - PubMed
-
- Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, et al. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 −1082G allele in a Zimbabwean cohort of HIV-1-infected adults. Aids. 2007;21:2283–91. - PubMed
-
- Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346–55. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI69501/AI/NIAID NIH HHS/United States
- K01 AI062435/AI/NIAID NIH HHS/United States
- R01 AI066992/AI/NIAID NIH HHS/United States
- AI 36219/AI/NIAID NIH HHS/United States
- U01 AI068636/AI/NIAID NIH HHS/United States
- AI062435/AI/NIAID NIH HHS/United States
- M01 RR000080/RR/NCRR NIH HHS/United States
- P30 AI036219/AI/NIAID NIH HHS/United States
- UM1 AI069472/AI/NIAID NIH HHS/United States
- 5 RO1 AI066992-04/AI/NIAID NIH HHS/United States
- UM1 AI069501/AI/NIAID NIH HHS/United States
- AI U01 68635/AI/NIAID NIH HHS/United States
- U01 AI069501/AI/NIAID NIH HHS/United States
- AI069472/AI/NIAID NIH HHS/United States
- AI 68636/AI/NIAID NIH HHS/United States
- U01 AI069472/AI/NIAID NIH HHS/United States
- UM1 AI068636/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
